ARC2172: Phase Ib started

Nuvelo began a dose-escalation, U.S. Phase Ib trial to evaluate a 2 mg/kg bolus of intravenous NU172 followed by up to 4 hours of continuous dosing in about 30 healthy volunteers. The compound is part...